Breast Surgery Practice Questions

Q: A 4 cm breast nodule with an ipsilateral mobile lymph node in the axilla, what is the correct TNM staging?

T2N1M0. ### Explanation The TNM staging system for breast cancer is a cornerstone of surgical oncology. To solve this question, we must break down the clinical findings based on the AJCC 8th Edition criteria. **1. Why T2N1M0 is correct:** * **T (Tumor Size):** The nodule is **4 cm**. T2 is defined as a tumor >2 cm but ≤5 cm in its greatest dimension. * **N (Nodal Status):** The presence of an **ipsilateral mobile lymph node** in the axilla corresponds to **N1**. (N2 would involve fixed/matted nodes or internal mammary involvement). * **M (Metastasis):** In the absence of mentioned distant spread, it is staged as **M0**. * Combining these, the stage is **T2N1M0**. **2. Why other options are incorrect:** * **T2N2M0:** Incorrect because N2 requires "fixed" or "matted" axillary nodes, or clinically detected internal mammary nodes in the absence of axillary nodes. "Mobile" nodes are strictly N1. * **T1N1M0:** Incorrect because T1 is defined as a tumor ≤2 cm. This patient’s tumor is 4 cm. * **T3N2M1:** Incorrect on all counts. T3 is >5 cm; N2 implies fixed nodes; M1 implies distant metastasis (not mentioned). **Clinical Pearls for NEET-PG:** * **T-Staging Cheat Sheet:** T1 (≤2 cm), T2 (2–5 cm), T3 (>5 cm), T4 (Extension to chest wall/skin, regardless of size). * **N-Staging Key:** N1 = Mobile axillary nodes; N2 = Fixed/Matted axillary nodes; N3 = Supraclavicular, infraclavicular, or internal mammary + axillary nodes. * **Inflammatory Carcinoma:** Always staged as **T4d**, regardless of the actual size of the underlying mass. * **Dimpling vs. Peau d'orange:** Skin dimpling (tethering to Cooper’s ligament) does not change T-stage, but *Peau d'orange* or skin ulceration classifies it as T4.

Q: Which of the following statements regarding Paget's disease of the breast is true?

It presents with nipple-areolar eczematous changes.. **Explanation:** **Paget’s disease of the breast** is a rare manifestation of breast cancer characterized by the presence of malignant **Paget cells** (large, pale cells with prominent nucleoli) within the epidermis of the nipple-areolar complex. 1. **Why Option B is Correct:** The hallmark clinical presentation is an **eczematous-like lesion** of the nipple that may spread to the areola. It typically presents with erythema, scaling, crusting, or ulceration. Unlike simple eczema, Paget’s disease usually starts at the nipple and spreads peripherally, and it does not respond to topical steroids. 2. **Why the Other Options are Incorrect:** * **Option A:** There is **no clinical or pathological link** between Paget’s disease of the breast and Paget’s disease of the bone (a disorder of bone remodeling). They simply share the same namesake (Sir James Paget). * **Option C:** While Paget’s disease is associated with underlying **Ductal Carcinoma in Situ (DCIS)** in about 40% of cases, the remaining 60% have an underlying **Invasive Ductal Carcinoma (IDC)**. Therefore, axillary lymph node involvement is possible and depends on the stage of the underlying malignancy. * **Option D:** It is rare, accounting for only **1–4%** of all newly diagnosed breast cancers, not 10–15%. **High-Yield Clinical Pearls for NEET-PG:** * **Pathogenesis:** The "Epidermotropic Theory" suggests cancer cells migrate from underlying lactiferous ducts to the nipple skin. * **Diagnosis:** A **full-thickness punch biopsy** of the nipple is the gold standard. * **Key Histology:** PAS-positive, diastase-resistant cells (due to mucin content). * **Management:** Requires evaluation for underlying malignancy via mammography/MRI. Treatment involves mastectomy or breast-conserving surgery (central lumpectomy) plus radiotherapy.

Q: In inflammatory carcinoma of the breast with axillary metastasis, what is the treatment of choice?

None of the above. **Explanation:** The treatment of choice for **Inflammatory Breast Cancer (IBC)** is a multimodal approach, and the correct sequence is critical. The correct answer is "None of the above" because all listed options suggest primary surgery (mastectomy) as the first step, which is contraindicated in IBC. **1. Why "None of the above" is correct:** Inflammatory Breast Cancer is considered **Locally Advanced Breast Cancer (LABC)** and is staged as **T4d**. Because it is characterized by dermal lymphatic invasion and high systemic risk, the standard of care is **Multimodal Therapy** in a specific sequence: * **Step 1:** Neoadjuvant Chemotherapy (NACT) – to downstage the tumor and treat micrometastases. * **Step 2:** Modified Radical Mastectomy (MRM) – performed only if there is a good clinical response to NACT. * **Step 3:** Post-operative Radiotherapy – to reduce local recurrence. **2. Why other options are incorrect:** * **Options A, B, and C** all propose immediate surgery (Radical or Simple Mastectomy). In IBC, the skin is heavily involved with "cancerous lymphangitis." Primary surgery is avoided because it often results in positive margins, poor wound healing, and rapid local recurrence. Simple mastectomy (Option C) is also inappropriate as it does not address the axillary metastasis. **Clinical Pearls for NEET-PG:** * **Hallmark Sign:** *Peau d'orange* (due to dermal lymphatic obstruction). * **Diagnosis:** Requires a full-thickness **skin punch biopsy** showing tumor emboli in dermal lymphatics. * **Staging:** Always Stage IIIB (if N0-N2) or Stage IIIC (if N3). It is the most aggressive form of breast cancer. * **Surgery Type:** If surgery is performed after NACT, it must be **MRM**. Breast-conserving surgery is contraindicated in IBC.

Q: A 65-year-old woman with a 5 mm tubular cancer, ER positive, PR positive, and a negative sentinel lymph node, undergoes a lumpectomy and sentinel lymph node biopsy. What adjuvant treatment should be recommended?

Radiotherapy and hormonal therapy. ### Explanation The management of early-stage breast cancer is determined by the tumor size, nodal status, and receptor profile. This patient has a **T1a (5 mm), N0, ER/PR-positive** breast cancer. **1. Why Option D is Correct:** * **Radiotherapy:** The patient underwent a **Lumpectomy** (Breast Conserving Surgery - BCS). A fundamental principle in breast surgery is that BCS must always be followed by **Whole Breast Irradiation (WBI)** to reduce the risk of local recurrence. * **Hormonal Therapy:** Since the tumor is **ER/PR positive**, adjuvant endocrine therapy (e.g., Aromatase Inhibitors or Tamoxifen) is indicated to reduce the risk of both ipsilateral recurrence and contralateral new primary breast cancers. **2. Why Other Options are Incorrect:** * **Option A:** Chemotherapy is generally omitted in "favorable" histologies like **Tubular carcinoma**, especially when the tumor is 70 years with small, node-negative, ER+ tumors) where the absolute benefit of radiation is minimal. At 65, radiotherapy remains the standard of care post-BCS. **3. Clinical Pearls for NEET-PG:** * **Tubular Carcinoma:** A "favorable" histological subtype of invasive ductal carcinoma with an excellent prognosis. * **BCS Equation:** BCS + Radiotherapy = Modified Radical Mastectomy (MRM) in terms of overall survival. * **Sentinel Lymph Node Biopsy (SLNB):** Indicated for all clinically N0 patients to avoid the morbidity of Axillary Lymph Node Dissection (ALND). * **Adjuvant Endocrine Therapy:** Standard duration is 5 years; Aromatase Inhibitors (Anastrozole/Letrozole) are preferred in postmenopausal women.

Q: A 43-year-old lady presents with a 5 cm lump in her right breast and a 3 cm node in the supraclavicular fossa. According to the latest AJCC staging system, which TNM stage does she belong to?

T2N3M0. ### Explanation This question tests the application of the **AJCC TNM Staging System** for breast cancer, specifically focusing on the classification of regional lymph nodes. **1. Why T2N3M0 is Correct:** * **T (Tumor Size):** The lump is 5 cm. According to AJCC, **T2** is defined as a tumor >2 cm but ≤5 cm. * **N (Node Status):** The presence of a **supraclavicular lymph node** (level III axillary/supraclavicular) is classified as **N3c**. In the TNM system, any N3 involvement automatically places the patient in Stage IIIC, regardless of T size (provided no distant metastasis is present). * **M (Metastasis):** Supraclavicular nodes are considered **regional** lymph nodes in breast cancer, not distant metastasis (M1). Therefore, the stage is **M0**. **2. Why Other Options are Incorrect:** * **A & B (T2/T1 N0 M1):** These are incorrect because supraclavicular nodes are N3 (regional), not M1 (distant). M1 would involve organs like the lungs, liver, or bone. * **D (T2N2M0):** N2 refers to fixed/matted axillary nodes or internal mammary nodes. Supraclavicular involvement is more advanced and categorized as N3. **Clinical Pearls for NEET-PG:** * **N1:** Mobile ipsilateral level I/II axillary nodes. * **N2:** Fixed/matted axillary nodes OR internal mammary nodes in the absence of axillary nodes. * **N3:** Infraclavicular (N3a), Internal mammary + Axillary (N3b), or **Supraclavicular (N3c)** nodes. * **High-Yield Fact:** Ipsilateral supraclavicular node involvement was once considered M1 but is now classified as **N3c** (Stage IIIC). Contralateral supraclavicular nodes, however, are still considered **M1**.

Q: Which of the following is NOT a treatment for gynecomastia?

None of the above. **Explanation:** Gynecomastia is the benign proliferation of glandular breast tissue in males. The management strategy depends on the underlying cause, the duration of the condition, and the patient's symptoms (pain or cosmetic distress). **Why "None of the above" is correct:** All the listed options (A, B, and C) are recognized and valid treatment modalities for gynecomastia. Since the question asks which is **NOT** a treatment, and all provided options are indeed treatments, "None of the above" is the correct choice. **Analysis of Options:** * **Hormonal Therapy (Option A):** Used primarily in the early "florid" phase (usually <1 year). Selective Estrogen Receptor Modulators (SERMs) like **Tamoxifen** are the most common medical treatments. Other options include Aromatase inhibitors or Danazol. * **Simple Mastectomy (Option B):** This involves the surgical removal of the breast tissue and is indicated for severe (Grade III) gynecomastia or when malignancy is suspected. * **Subcutaneous Liposuction Mastectomy (Option C):** This is the preferred surgical approach for cosmetic results. It combines liposuction (to remove fatty tissue) with a periareolar incision to excise the glandular disc (Webster’s incision). **NEET-PG High-Yield Pearls:** * **Most common cause:** Idiopathic, followed by persistent pubertal gynecomastia. * **Drugs causing gynecomastia:** Remember the mnemonic **"DISCO"**: **D**igoxin, **I**soniazid, **S**pironolactone (most common drug cause), **C**imetidine, **O**estrogens. * **Grading:** Simon’s Classification is used to grade the severity. * **Pathology:** Characterized by an increase in stroma and ducts; notably, **males do not develop acini/lobules** unless exposed to extreme progestational stimulation.

Q: Serous or serosanguinous nipple discharge may be suggestive of all of the following except?

Mastitis. **Explanation:** The correct answer is **Mastitis**. **1. Why Mastitis is the correct answer:** Mastitis is an inflammatory/infectious condition of the breast, typically associated with lactation. It characteristically presents with **purulent (pus-like)** nipple discharge, along with systemic symptoms like fever and local signs of inflammation (rubor, tumor, calor, dolor). Serous (straw-colored) or serosanguinous (blood-tinged) discharge is not a feature of acute infection but rather suggests proliferative or neoplastic changes in the ductal epithelium. **2. Analysis of Incorrect Options:** * **Intraductal Papilloma:** This is the **most common cause** of serosanguinous or bloody nipple discharge. It is a benign growth within the duct. * **Carcinoma:** While less common than benign causes, breast cancer (especially Ductal Carcinoma In Situ) can present with serous or bloody discharge, particularly if it involves the major lactiferous ducts. * **Duct Ectasia:** This involves the dilation of subareolar ducts. While it often presents with thick, multicolored (green/creamy) discharge, it can also present with serous or blood-stained discharge due to periductal inflammation and erosion. **3. NEET-PG High-Yield Pearls:** * **Most common cause of bloody nipple discharge:** Intraductal Papilloma. * **Most common cause of milky discharge (non-lactational):** Hyperprolactinemia (Galactorrhea). * **Management:** Any spontaneous, unilateral, single-duct discharge (especially if bloody) requires a **Triple Assessment** to rule out malignancy. * **Surgical Procedure:** For single duct discharge, **Microdochectomy** is the procedure of choice; for multiple duct discharge (e.g., ectasia), **Hadfield’s procedure** (Total Duct Excision) is performed.

Q: All are risk factors for Carcinoma breast except?

Early menopause. **Explanation:** The primary driver for the development of breast carcinoma is **prolonged cumulative exposure to estrogen**. Estrogen promotes the proliferation of mammary epithelial cells, increasing the likelihood of DNA mutations. **Why Early Menopause is the Correct Answer:** Early menopause (cessation of menstruation before age 45) is actually a **protective factor**, not a risk factor. It shortens the total duration of the "estrogen window" in a woman’s life. Conversely, **late menopause** (after age 55) is a significant risk factor because it extends the period of hormonal exposure. **Analysis of Incorrect Options:** * **Nulliparity:** Pregnancy causes a temporary cessation of the menstrual cycle and induces terminal differentiation of breast cells. Women who have never been pregnant (nulliparous) have more menstrual cycles and higher lifetime estrogen exposure. * **Obesity:** In postmenopausal women, adipose tissue is the primary site for the peripheral conversion of androstenedione to estrone (via the enzyme **aromatase**). Increased BMI leads to higher circulating estrogen levels. * **Lack of Breastfeeding:** Breastfeeding suppresses ovulation (lactational amenorrhea) and promotes the maturation of ductal epithelium. A lack of breastfeeding results in more ovulatory cycles and higher risk. **High-Yield Clinical Pearls for NEET-PG:** * **The "Estrogen Window" Concept:** Risk increases with **early menarche** ( 55 years). * **First Full-term Pregnancy:** Having the first child after age 30 is a greater risk factor than nulliparity. * **Genetic Factors:** BRCA1 (Chromosome 17) and BRCA2 (Chromosome 13) are the most common high-penetrance mutations. * **Protective Factors:** Early pregnancy, prolonged breastfeeding, physical activity, and early menopause.

Q: Which tumor may occur in the residual breast or overlying skin following wide local excision and radiotherapy?

Angiosarcoma. ### Explanation **Correct Answer: D. Angiosarcoma** **Reasoning:** Angiosarcoma of the breast is a rare but highly aggressive malignant tumor of the vascular endothelium. It occurs in two distinct clinical settings: 1. **Primary Angiosarcoma:** Occurs sporadically in younger women (30–40s) without prior risk factors. 2. **Secondary Angiosarcoma (Radiation-Induced):** This is the specific entity described in the question. It occurs in the residual breast tissue or overlying skin following **Breast Conserving Surgery (Wide Local Excision) and Radiotherapy**. The typical latency period is **5–10 years** post-radiation. It often presents as painless, bluish-red skin discoloration or nodules that can be mistaken for simple bruising. **Why Incorrect Options are Wrong:** * **A. Leiomyosarcoma:** This is a malignant tumor of smooth muscle. While it can occur in the skin or retroperitoneum, it is not a recognized complication of breast radiotherapy. * **B & C. Squamous and Basal Cell Carcinoma:** These are common skin cancers primarily associated with UV radiation (sun exposure). While chronic radiation dermatitis can theoretically predispose to SCC, Angiosarcoma is the classic, high-yield association specifically linked to post-mastectomy/post-lumpectomy radiation and lymphedema. **High-Yield Clinical Pearls for NEET-PG:** * **Stewart-Treves Syndrome:** This refers to angiosarcoma arising in a limb affected by **chronic lymphedema** (classically the arm following a radical mastectomy with axillary lymph node dissection). * **Latency:** Radiation-induced angiosarcoma has a shorter latency (approx. 7 years) compared to other radiation-induced solid tumors (20+ years). * **Diagnosis:** Requires a full-thickness skin biopsy. * **Prognosis:** Very poor due to high rates of local recurrence and hematogenous metastasis (especially to the lungs).

Question 1

A 4 cm breast nodule with an ipsilateral mobile lymph node in the axilla, what is the correct TNM staging?

Accepted Answer

T2N1M0

Answer

T2N2M0

Answer

T1N1M0

Answer

T3N2M1

Question 2

Which of the following statements regarding Paget's disease of the breast is true?

Accepted Answer

It presents with nipple-areolar eczematous changes.

Answer

It usually precedes the development of Paget's disease of bone.

Answer

It does not involve axillary lymph nodes because it is a manifestation of intraductal carcinoma only.

Answer

It accounts for 10-15% of all newly diagnosed breast cancers.

Question 3

In inflammatory carcinoma of the breast with axillary metastasis, what is the treatment of choice?

Accepted Answer

None of the above

Answer

Radical mastectomy plus chemotherapy

Answer

Radical mastectomy plus radiotherapy

Answer

Simple mastectomy plus radiotherapy

Question 4

A 65-year-old woman with a 5 mm tubular cancer, ER positive, PR positive, and a negative sentinel lymph node, undergoes a lumpectomy and sentinel lymph node biopsy. What adjuvant treatment should be recommended?

Accepted Answer

Radiotherapy and hormonal therapy

Answer

Chemotherapy and radiation

Answer

Radiation treatment only

Answer

Hormonal therapy only

Question 5

A 43-year-old lady presents with a 5 cm lump in her right breast and a 3 cm node in the supraclavicular fossa. According to the latest AJCC staging system, which TNM stage does she belong to?

Accepted Answer

T2N3M0

Answer

T2N0M1

Answer

T1N0M1

Answer

T2N2M0

Question 6

Which of the following is NOT a treatment for gynecomastia?

Accepted Answer

None of the above

Answer

Hormonal therapy

Answer

Simple mastectomy

Answer

Subcutaneous liposuction mastectomy

Question 7

Serous or serosanguinous nipple discharge may be suggestive of all of the following except?

Accepted Answer

Mastitis

Answer

Carcinoma

Answer

Duct ectasia

Answer

Intraductal papilloma

Question 8

All are risk factors for Carcinoma breast except?

Accepted Answer

Early menopause

Answer

Nulliparity

Answer

Obesity

Answer

Lack of breast feeding

Question 9

Which tumor may occur in the residual breast or overlying skin following wide local excision and radiotherapy?

Accepted Answer

Angiosarcoma

Answer

Leiomyosarcoma

Answer

Squamous cell carcinoma

Answer

Basal cell carcinoma

Question 10

During breast reconstruction surgery, which of the following structures is preserved?

Accepted Answer

Pectoralis major

Answer

Pectoralis minor

Answer

Serratus anterior

Answer

Nipple areola complex

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?